Related Experiment Video

Updated: Jul 18, 2026

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
07:53

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

Published on: January 9, 2019

Drug design targeting the main protease, the Achilles' heel of coronaviruses

Haitao Yang1, Mark Bartlam, Zihe Rao

  • 1National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.

Current Pharmaceutical Design
|December 16, 2006
PubMed

Insights

Coronaviruses cause severe diseases. Targeting the main protease (M(pro)) with new inhibitors offers a promising strategy for developing broad-spectrum antiviral drugs against current and future coronavirus threats.

Area of Science:

  • Virology
  • Drug Discovery
  • Structural Biology

Background:

  • Coronaviruses (CoVs) are a genus of viruses causing prevalent and often severe diseases in humans and animals.
  • Severe acute respiratory syndrome (SARS) emerged in 2003, caused by a novel coronavirus, highlighting the threat of emerging CoV infections.
  • Currently, no effective therapies exist for SARS-CoV, with vaccines and drugs under development.

Purpose of the Study:

  • To review recent biological and structural studies of Coronaviruses (CoVs).
  • To summarize the development of inhibitors targeting the CoV main protease (M(pro)).
  • To explore the potential of M(pro) inhibitors as wide-spectrum antiviral drugs.

Main Methods:

  • Literature review of biological and structural studies on CoV M(pro).
  • Analysis of inhibitor development strategies targeting CoV M(pro).
  • Assessment of M(pro)s role in viral replication and gene expression.

Main Results:

  • The CoV main protease (M(pro)) is crucial for viral gene expression and replication.
  • Recent biological and structural insights provide a foundation for drug design.
  • Several inhibitor development strategies targeting CoV M(pro) have been explored.

Conclusions:

  • Inhibitors targeting CoV M(pro) represent a promising therapeutic strategy.
  • These inhibitors have the potential to be developed into wide-spectrum antiviral drugs.
  • This approach could combat existing and future emerging CoV-associated diseases.

More Related Videos

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

Engineering Antiviral Agents via Surface Plasmon Resonance13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

Related Concept Videos

Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Coronavirus01:29

Coronavirus

Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), are enveloped viruses characterized by their single-stranded, positive-sense RNA genome and helical nucleocapsid structure. The hallmark of these viruses is their club-shaped spike (S) glycoproteins that protrude from the viral envelope, facilitating attachment to host cells. Typically, coronaviruses infect the upper respiratory tract, often causing mild or asymptomatic disease. However, certain strains like...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...